Introduction
The development of novel antibacterial agents that are capable of killing resistant bacteria is urgent due to the challenges posed by a number of, both Gram-positive and Gram-negative, pathogens with multi-and sometimes pan-drug resistance [1] [2] [3] [4] . An acronym, ESKAPEE has been derived from the organisms recognised as the major threats (Enterococcus faecalis, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp and Escherichia coli) although there are a number of other organisms that may become equally challenging to treat in the clinic [2] [3] [4] [5] [6] [7] . The pipeline of antibiotics is essentially empty and very few compounds are in the early stages of clinical trials [2, 3, [8] [9] [10] . Of the Gram-positive pathogens, increasing resistance in S. aureus has become a major clinical problem, particularly in the hospital environment, causing significant morbidity and mortality in both healthy hosts and those with underlying comorbidities [11] [12] [13] . S. aureus is found commensally on nasal passages, skin and mucous membranes. The emergence of resistant strains of S. aureus has been reported since the mid-1900s. More recently MRSA has become the number one cause of hospital-associated infections, and a large proportion of these infections are caused by MRSA [14] . Approximately 150,000 infections are caused by MRSA in the Europe and the mortality rate is estimated between 15-25% [15] . Therefore, development of novel antimicrobial agents for the treatment of infections caused by MDR S. aureus is an urgent priority.
Classical antimicrobial drug discovery involves in vitro screening for antimicrobial candidates, Structure Activity Relationship (SAR) analysis, followed by in vivo testing for toxicity and efficacy. However, the high cost of drug development, coupled with a relatively short window of use to gain a return on investment for new antibiotics, have resulted in a waning interest in 4 antibiotic discovery among many pharmaceutical companies [16] . Lack of novel chemical scaffolds with antibiotic activity has further compounded the problem [2] , and no new classes of antibiotics have been found since daptomycin, leading to a discovery void [17] . One of the key approaches in discovering new antibacterial drugs is the modification of existing chemical scaffolds, almost all the antibacterial drugs that reached the market after the 1960s are synthetic derivatives of core-scaffolds discovered between 1930 and 1950. Modifications and introductions of novel chemical moieties on the core-scaffold resulted in new generations of molecules typically characterized by greater potency, a broader spectrum of activity and capability of avoiding the mechanism of resistance [2] . In a bid to identify a new chemical scaffold with activity against MDR Gram-positive bacteria, we explored nitrofuran-isoxazoline scaffold that has been previously reported for notable activity against Mycobacterium tuberculosis [18] [19] [20] [21] . Incorporation of a pyridyl side chain with a piperazine spacer has resulted in compounds (Fig 1a) with significant activity against MDR Staphylococcus species including MRSA strains. Interestingly, the position of the nitrogen atom in the pyridine ring appears to be very important for antibacterial activity with 3-pyridyl analogue showed the most notable activity followed by the 2-pyridyl analogue while the 4-pyridyl analogue is either inactive or active only at a very high concentration. Incorporation of electron withdrawing or donating groups in the terminal pyridine ring retained activity of the 3-pyridyl compounds. The piperazine spacer appeared to have a notable effect on the antimicrobial efficacy as compounds without the piperazine spacers (Fig 1b) were found to be less active compared to their counterparts with piperazine spacers, except the 4-pyridyl analogues which showed some gain of activity after the removal of the piperazine spacer. The activity range of the eight compounds synthesized provides SAR information about this modified chemical scaffold and its antimicrobial profile that can be further explored to develop more potent analogues. 
Materials and Methods

Chemistry
All solvents and reagents for the synthesis were obtained from commercial available sources including Sigma-Aldrich, Fisher Scientific, Fluorochem and Alfa Aesar. Thin-layerchromatography (TLC) analysis was performed on silica gel plates (E. Merck silica gel 60 F254 plates) and visualized by ultra-violet (UV) radiation at 254 nm. Flash chromatography for the purification of compound was performed with silica gel as a stationary phase (Merck 60, 230-400 mesh). 1 H and 13 C nuclear magnetic resonance (NMR) analyses were performed on a Bruker Spectrospin 400 Hz spectrometer. LC-MS analyses were performed on a Waters Alliance 2695 system, eluting in gradient with a flow rate of 0.5 mL/min according to the condition reported 6 herein in Table S1 : The analyses were performed on a Monolithic C18 50 X 4.60 mm column by Phenomenex. UV detection was performed on a Diode Array Detector. Mass spectra were registered in both ESI+ and ESI-mode.
Synthesis of novel pyridyl nitrofuranyl isoxazolines with piperazine spacer, 8a-e
Synthesis of tert-butyl 4-(4-vinylphenyl)piperazine-1-carboxylate (3)
A mixture of 1 (1.06 g, 5.80 mmol, 1 eq.), NaO t Bu (2.4 eq.), PdCl 2 [P(o-Tol) 3 ] 2 (0.06 eq.) and 2 (2 eq.) dissolved in toluene (50 mL) was left at reflux at 100°C with stirring in N 2 atmosphere for 3 hours. The crude of reaction was filtered on Celite eluting with DCM and then concentrated under reduced pressure. Purification by column chromatography on silica gel (mobile phase: 9/1, v/v, hexane/EtOAc) provided 3 (1.19 g, 73%) as a yellow solid. 1 
Synthesis of N-hydroxy-5-nitrofuran-2-carbimidoyl chloride (5)
5-nitro-2-furaldoxime 4 (1.5 g, 10 mmol, 1 eq.) was dissolved in a solution of HCl 0.5M (1.1 eq., 916 µl) in DMF (10.55 mL) and subsequently oxone (1.1 eq.) was added. The reaction mixture was left under magnetic stirrer at room temperature until TLC showed total consumption of the starting material. The reaction mixture was diluted with water (100 mL) and extracted with 7 EtOAc (3 x 40 mL). The organic layer was then washed with HCl 0.5 M aqueous solution (100 mL) and brine (100 mL). The collected organic phase was dried on MgSO 4 , filtered and concentrated under reduced pressure providing 5 (1.87 g, yield was assumed 100%) as a yellow solid.
Synthesis of tert-butyl 4-(4-(3-(5-nitrofuran-2-yl)-4,5-dihydroisoxazol-5yl)phenyl)piperazine-1-carboxylate (6)
Triethylamine (1.20 eq) was added to a solution of 3 (500 mg, 1.70 mmol 1 eq.) and 5 (1.20 eq.) in CHCl 3 (5 mL). The reaction mixture was left stirring in N 2 atmosphere for 20 hours until TLC showed total consumption of the starting material. At that point CHCl 3 (11 mL) was added to the reaction mixture and the organic phase was washed with brine (4 x 10 mL) and then dried on (m, 4H), 1.39 (s, 9H). 13 
General procedure for synthesis of final products (8a-e)
Concentrated hydrochloric acid solution (14 mL) was added to a solution of 6 (430 mg, 0.97 mmol, 1 eq.) in MeOH (15 mL) and the reaction mixture was left under magnetic stirrer at room temperature for 15 minutes until TLC showed total removal of the protecting group. The solution was then concentrated under reduced pressure to provide 7 (348 mg, 100%) as white solid.
Finally, the corresponding bromomethyl pyridine hydrobromide or chlorometyl pyridine hydrochloride derivatives or bromomethyl 4-substitited pyridine derivatives (1.5 eq.) was added to a solution of 7 (from 61 mg to 177 mg, 1 eq.) in DMF (8 mL) in the presence of K 2 CO 3 (3 eq.). The reaction mixture was stirred at 50°C under N 2 atmosphere for 16 hours. Obtained 68 mg (98%), as a dark yellow solid. 1 
3-(5-nitrofuran-2-yl)-5-(4-(4-(pyridin-3-ylmethyl)piperazin-1-yl)phenyl)-4,5dihydroisoxazole (8b).
Obtained 44 mg (33.3%) as a yellow solid. 1 13 
3-(5-nitrofuran-2-yl)-5-(4-(4-(pyridin-4-ylmethyl)piperazin-1-yl)phenyl)-4,5dihydroisoxazole (8c).
Obtained 104 mg (51%) as a yellow solid. 1 
5-(4-(4-((6-fluoropyridin-3-yl)methyl)piperazin-1-yl)phenyl)-3-(5-nitrofuran-2-yl)-4,5dihydroisoxazole (8d).
Obtained 11 mg (10.6%) as a yellow solid. 1 13 
5-(4-(4-((6-methoxypyridin-3-yl)methyl)piperazin-1-yl)phenyl)-3-(5-nitrofuran-2-yl)-4,5dihydroisoxazole (8e)
Obtained 37 mg (34.6%) as a yellow solid. Obtained 37 mg (34.6%) as a yellow solid. s., 4H). 13 
Synthesis of novel pyridyl nitrofuranyl isoxazolines without the piperazine spacer, 10a-c
Synthesis of 5-(4-bromophenyl)-3-(5-nitrofuran-2-yl)-4,5-dihydroisoxazole (9).
To a solution of 4-bromostyrene (400 mg, 2.18 mmol, 1 eq.) in CHCl 3 (10 mL), 0.36 mL (1.20 eq) trimethylamine and 5 (500 mg, 2.62 mmol, 1.20 eq) were added. The reaction mixture was 13 
Synthesis of 3-(5-nitrofuran-2-yl)-5-(4-(pyridin-2-yl)phenyl)-4,5-dihydroisoxazole (10a).
Tetrakis(triphenylphosphine)palladium(0) (69.2 mg, 0.06 mmol, 0.08 eq.), K 2 CO 3 (290.20 mg, 2.10 mmol, 3 eq.) and pyridine-2-boronic acid (129.04 mg, 1.05 mmol, 1.50 eq.) were added to a solution of 9 (262.95 mg, 0.70 mmol, 1 eq.) in dioxane (5 mL) and water (0.50 mL). The reaction mixture was stirred at reflux under an N 2 atmosphere for 72 hrs. The reaction was not completed, but it was decided to work up the reaction mixture to prevent formation of further impurities. The reaction was filtered on a Celite pad, with the solvent evaporating under reduced pressure and the crude reaction mixture dissolving in ethyl acetate (10 mL). This solution was washed with water and the aqueous layer was extracted with ethyl acetate (3 x 10 mL). The 
General procedure for the synthesis of pyridyl isoxazolines without the piperazine linker (10b-c)
[Pd 2 (dba) 3 ] (48.9 mg, 0.053 mmol, 0.067 eq.), Tricyclohexylphosphine (131.24 mg, 0.47 mmol, 0.6 eq.), K 3 PO 4 (496.71 mg, 2.34 mmol, 3 eq.) and the desired pyridine boronic acid (143.80 mg, 1.17 mmol, 1.5 eq.) were added to a solution of 9 (262.95 mg, 0.70 mmol, 1 eq.) in dioxane (5 mL) and water (0.50 mL). The reaction mixture was stirred at reflux under N 2 atmosphere for 20h at which point LC-MS monitoring showed complete consumption of the starting material.
The reaction was then filtered on a Celite pad, the solvent evaporated under reduced pressure and the evaporated crude reaction mixture was dissolved in ethyl acetate (10 mL). This solution was washed with water and the aqueous layer was extracted with ethyl acetate (3 x 10 mL). The combined organic layer was dried over MgSO 4 and evaporated in vacuo. The obtained crude product was then purified by column chromatography on silica gel (mobile phase: from 100% DCM to 95/5, v/v, DCM/acetone) obtaining the final products 10b-c.
3-(5-nitrofuran-2-yl)-5-(4-(pyridin-3-yl)phenyl)-4,5-dihydroisoxazole (10b).
Obtained 24 mg as a yellow solid. 1 min and re-suspended in fresh medium.
MTT Assay
The cells were grown in normal cell culture conditions at 37 ºC under a 5% CO 2 humidified atmosphere using appropriate medium. The cell count was adjusted to 10 5 cells/mL and 10,000 cells were added per well. The cells were incubated for 24 hours and 1 μl of the appropriate ligand concentrations were added to the wells in triplicates. After 96 hours of continuous exposure to each compound, the cytotoxicity was determined using the 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Lancaster Synthesis Ltd, UK) colorimetric assay. [34 Absorbance was quantified by spectrophotometry at λ = 570 nm (Envision Plate Reader, PerkinElmer, USA). IC 50 values were calculated by a dose-response analysis using the Prism GraphPad Prism® software.
Microbiological Evaluation of the Compounds
Determination of minimum inhibitory concentration
MICs were determined using the broth microdilution method as outlined in the CLSI guidelines [22] . Cell growth in Muller Hinton Broth (MHB) was determined by measuring optical density (600 nm) using a FLUOstar Omega microplate reader (BMG Labtech). The MIC was determined as the lowest concentration of drug at which growth was below an optical density of 0.10 at 600 nm after 20 hours growth. Tests were conducted in triplicate.
Determination of minimum bactericidal concentration
To determine the minimum bactericidal concentration (MBC), 10ul was taken from all wells of the MIC plate at and above the MIC and spotted onto a tryptic soy agar plate. The agar plates were incubated at 37 C for 24 hours and the MBC was defined as the concentration at which no colonies were seen. The ratio MBC/MIC that was used to evaluate if the compound is bactericidal (MBC/MIC = 1 or 2) or bacteriostatic (MBC/MIC = 4 or 16).
Time kill assays.
Flasks of MHB were inoculated with test organism at a concentration ~10 6 cfu/mL in a total volume of 50 mL. The antimicrobial agents were then added at a concentration of 4 x MIC and incubated at 37 C in a shaking incubator at 200 rpm. Samples (0.10 mL) were taken from each 16 sample every hour for 8 hours and at 24 hours following inoculation. The effect on bacterial growth was determined using a modification of the Miles Misra dilution methods to estimate viable counts.
Results
Chemistry
The synthetic scheme for the pyridyl nitrofuranyl isoxazoline compounds with piperazine spacer (8a-e) is shown in Fig 2. First, the piperazine spacer was installed on p-bromo styrene by a palladium-catalyzed aromatic amination reaction[23] on 1 with N-Boc piperazine in 73% yield.
Next, the 5-nitro-2-furaldoxime 4 was converted to the corresponding hydroximoyl chloride 5
using Oxone and HCl [24] in DMF which upon treatment with olefin 3, underwent a [3 + 2] regioselective cycloaddition [25] under inert condition to give the reference Boc-protected isoxazoline 6 in 74.3% yield. The Boc-deprotection of 6 was carried out in a methanolic solution of HCl in room temperature in quantitative yield. Finally, the free amine 7 was treated with 2- To explore the role of the piperazine spacer between the phenyl ring and the terminal pyridyl ring, three more compounds were designed in which the piperazine spacer was removed and the phenyl ring was directly coupled to the pyridyl ring using Suzuki coupling. These compounds (10a-c) were synthesized according to synthetic scheme reported in Fig 3. First, the 5-nitro-2-18 furaldoxime 4 was converted to the corresponding hydroximoyl chloride 5 using Oxone and HCl [24] in DMF which underwent a [3 + 2] regioselective cycloaddition [25] with p-bromo styrene under inert condition to afford the Suzuki substrate 9 in 70% yield. Finally, the Suzuki cross-coupling reactions between 9 and the pyridyl-3-boronic acid and pyridyl-4-boronic acid were carried out using Pd 2 (dba) 3 as a catalyst under inert condition in the presence of tricyclohexylphosphine and K 3 PO 4 to afford 10b, and 10c. The Suzuki reaction between 9 and pyridyl-2-boronic acid did not proceed under same condition, and was carried out using tetrakis palladium as the catalyst with a modest 10% yield to afford 10a. 
Microbiological Evaluation
MIC and MBC Determination
The antibacterial evaluation of compound 6, 8a-c and 10a-c were carried out using the broth microdilution method as outlined in the CLSI guidelines [22] . Initially, the compounds were Table 1) , and 8c showed activity similar to that of 6 ( Table 1) Compounds 8a and 8b were tested for their minimum bactericidal concentration (MBC) and the ratio of MBC to MIC was calculated to determine the bactericidal vs bacteriostatic mode of action the compounds. Both 8a and 8b showed MBC of ≥128 µg/mL against the MSSA 9144 strain with an MBC to MIC ratio of 8 suggesting a bacteriostatic mode of action as compounds are usually regarded bactericidal if the MBC is no more than four times MIC. Both compounds showed MBC values of >128 µg/mL against the EMRSA strains with MBC to MIC ratio of greater than 4 in each cases.
Compounds 8a and 8b were tested against an extended panel of S. aureus and S. epidermidis strains from a range of different lineages ( 
Time Kill Assay
Compound 8b was selected for time kill analysis against the EMRSA-15 strain to determine whether 8b was bactericidal or bacteriostatic. 8b appeared to be bacteriostatic against with activity against EMRSA-15 comparable to that of ciprofloxacin which was used as a control (Fig4). There was no evidence of resistant colonies being selected for during the time-kill assays, but there were viable cells which survived the treatment process with 8b for EMRSA-15 with no significant reduction in the viable count between approximately 5 hours post treatment and the end of the time course at 24 hours (Fig 4) . The data suggests a bacteriostatic mode of action which is consistent with the MBC to MIC ratio reported in Table 3 . 
Cytotoxicity Screening
Finally, the compounds were tested for their cytotoxic potential against the cervical cancer cell line HeLa using the MTT assay [28] and the non-tumour lung fibroblast cell line WI-38 and the results are shown in Fig 5 and S1Table. Doxorubicin was used as a positive control in the MTT assay for comparison purpose. Doxorubicin showed notable cytotoxicity with an IC 50 of 71 nM (Fig 5) , but none of the compounds demonstrated a measurable IC 50 at the concentrations tested 24 and this lack of toxicity against the mammalian cells was encouraging from the anti-infective point of view as this chemical scaffold offers selective toxicity against prokaryotic cells. 
Discussion
Eight new pyridyl nitrofuranyl isoxazolines were successfully synthesized using solution phase linear chemistry. The compounds were derived from a reported molecule that has shown antitubercular activity but was found to be broadly inactive against both Gram-positive and against Gram-positive pathogens [30, 31] . The absolute MIC values for drug resistant strains that were susceptible against 8b were consistently lower for compound 8b (typically 4-16 µg/mL) than for the control antibiotic nitrofurantoin which may have a similar mechanism of action (i.e., nitrocompound toxicity) and shares structural similarity. Nitrofurantoin is used routinely in the United Kingdom and elsewhere for the treatment of urinary tract infections and the improved activity of 8b compared to nitrofurantoin is both encouraging and significant from a drugdiscovery point of view as there is significant opportunity to make medicinal chemistry modifications on the scaffold to develop more potent antibacterial agents. It should be noted that the MIC values of 8b were higher than that for ciprofloxacin (0.125-2 µg/mL), vancomycin (0.5-2 µg/mL) or amoxicillin (0.25-2 µg/mL), Given the different mode of action of these antibiotics, this is unsurprising and does not necessarily preclude the development of pyridyl nitrofuranyl isoxazolines as candidate antibiotics, especially given their low eukaryotic cell toxicity. Like nitrofurantoin, there are several antibiotics which are used routinely in the clinic and where the MIC for susceptible strains is higher than that observed for compound 8b. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) define resistance to nitrofurantoin as being an MIC of 64 µg/mL and above, for Staphylococcus spp. In contrast, S.aureus strains with an MIC of 2 µg/mL are defined as being resistant to ciprofloxacin. There is significant opportunity to make medicinal chemistry modifications on the scaffold, to develop more potent antibacterial agents.
Although this chemical scaffold showed a relatively narrow spectrum of activity, there is increasing support within the clinical community for this since they do not have wide ranging deleterious effects on the patients' normal flora. Narrow spectrum agents can eliminate resistance pressure on large sections of the microbiome, as these agents will be inactive against them, and thereby play a pivotal role in minimising spread or resistance [32] . The number of pipeline drugs presently undergoing clinical trials against MRSA is not particularly encouraging [33] and, although the pipeline is not completely empty, it is important to exploit existing as well as new chemical scaffolds to develop drug leads that can be optimized into clinical candidates.
Conclusion
Concern over antibiotic resistance is growing, and novel classes of antibiotics are needed. We have successfully modified a chemical scaffold that has previously shown activity against
Mycobacterium species, but was inactive against MDR Gram-positive pathogens, and introduced notable activity against MRSA strains. It was possible to obtain limited SAR information from 28 the compound set and this information can be useful to generate future compounds of this type.
The pyridyl nitrofuranyl isoxazoline 8b showed improved activity against a wider panel of drugresistant and sensitive Staphylococcus strains compared to nitrofurantoin which like these compounds shares nitrofuran group and may have a similar mechanism of action. The lack of mammalian toxicity and the opportunity to make medicinal-chemistry modifications make pyridyl nitrofuranyl isoxazoline scaffold an interesting starting point to develop more potent antibacterial agents against MDR Gram-positive pathogens.
